skip to Main Content

Looking Ahead: The Evolving Oncology Landscape

  • This page as PDF


Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.

The oncology landscape continues to evolve, with delays to preventative screenings and care during the COVID-19 pandemic and an influx of approved immunotherapy and other targeted therapy products. Stakeholders will be impacted by a changing payer mix with growth in managed markets, continued investment in diagnosis and treatment options, and a focus on value. Join us for a discussion on these shifts and what to expect going forward.

Key Topics:

  • Impact of COVID-19 on access and health equity, including insurance coverage shifts, changes in reimbursement, and telehealth adoption
  • Areas of innovation and market growth, including advances in diagnosis and treatment
  • Strategies to demonstrate value, especially for targeted therapies


Sarah Butler , Head, Client Solutions, Marketing & Operations

Sarah Butler specializes in evidence-based medicine, value-based contracting, and strategy development.

Roy Beveridge , Managing Director, Market Access & Reimbursement

Roy Beveridge, MD, a medical oncologist, provides insights and support across all Avalere practices, including the Center for Healthcare Transformation, Financial Services, and the Market Access team.

Omar Hafez , Managing Director, Market Access & Reimbursement

Omar advises a range of clients on issues including supply chain, drug pricing, launch strategy, and oncology market analytics and planning.

Allison Petrilla , Managing Director, Health Economics & Advanced Analytics

Allison Petrilla works closely with life sciences clients to design observational research studies, health economic evaluations, and market landscape assessments.

Sign up to receive more insights about COVID-19 Intel Center
Please enter your email address to be notified when new COVID-19 Intel Center insights are published.

Back To Top